Cargando…

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage

Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases. Physiologic pharmacokinetic models have been previously used to describe the absorption, distribution, metabolism, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, JE, LaCerte, C, Peyret, T, Gosselin, NH, Marier, JF, Hofmann, AF, Shapiro, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351006/ https://www.ncbi.nlm.nih.gov/pubmed/27743502 http://dx.doi.org/10.1111/cts.12421

Ejemplares similares

Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
por: John, Binu V., et al.
Publicado: (2021)

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
por: Yan, Kathleen, et al.
Publicado: (2021)

Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis
por: Roda, A, et al.
Publicado: (2017)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

SAT626 The Use Of Salivary Cortisol Measurement By Mass Spectrometry To Identify Low Serum Cortisol Values In Healthy Volunteers Receiving CRN04894, A Melanocortin 2 Receptor (MC2R) Antagonist
por: Ayala, Alejandro, et al.
Publicado: (2023)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes
por: McIlvride, Saraid, et al.
Publicado: (2019)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2018)

Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia
por: Pataia, Vanessa, et al.
Publicado: (2020)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2020)

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
por: Marier, Jean‐Francois, et al.
Publicado: (2021)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021)

Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat
por: Zhang, Hanlin, et al.
Publicado: (2021)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2018)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
por: Anfuso, Beatrice, et al.
Publicado: (2020)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

27558 Obeticholic acid (OCALIVA ®) protects against 2,8-dihydroxyadenine nephropathy in mice
por: Jones, Bryce, et al.
Publicado: (2021)

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease
por: Lee, Seung Min, et al.
Publicado: (2023)

Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature
por: Hvas, Christian Lodberg, et al.
Publicado: (2018)

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
por: Bowlus, Christopher L
Publicado: (2016)

Obeticholic Acid Protects against Gestational Cholestasis-Induced Fetal Intrauterine Growth Restriction in Mice
por: Chen, Wei, et al.
Publicado: (2019)

Obeticholic acid: Worsening bilirubin, pruritus and bleeding from portal hypertension: 4 case reports
Publicado: (2021)

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals
por: Ng, Cheng Han, et al.
Publicado: (2023)

Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects
por: Edwards, Jeffrey E., et al.
Publicado: (2017)

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
por: Goto, Toshihiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_blal07jdaci821ull25qlhedeh